GLPwatch
Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.
Pain Manag · 2024
Last updated 2026-05-28In a study of elderly patients with Type 2 diabetes and knee osteoarthritis, dulaglutide improved blood sugar control, reducing HbA1c from 8.7% to 6.5% over 6 months. It also decreased knee pain, reduced use of NSAID painkillers, and lowered body weight and BMI. The improvements in blood sugar control were strongly linked to reductions in pain.
AI summary of the abstract below.
| Journal | Pain Manag, 2024 |
|---|---|
| Citations | 7 |
| Relative citation ratio | 1.61 |
| NIH percentile | 67 |
| Molecules | dulaglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
This study aims to evaluate the dual benefits of dulaglutide in improving glycemic control and reducing knee OA pain. Elderly T2DM patients diagnosed with bilateral knee OA on conventional OA treatment for at least 3 months were studied for their glycemic metrics, OA pain scores and NSAID consumption at baseline, 3 months and 6 months. Significant improvements in glycemic control were observed, HbA1c decreased from 8.7% to 6.5% over 6 months. Pain scores, NSAID, body weight and BMI showed substantial reductions over time. Positive correlation (r = 0.73, < 0.001) was found between glycemic control and pain reduction. Dulaglutide improves glycemic control, knee joint OA pain and weight management in elderly patients with T2DM.
Verbatim abstract via PubMed 39301951 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).